RxDoctor Payments Data

Brenda Hines, MD

Sleep Medicine · Flowood, MSNPI 1932296589

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $42,558 of the $56,432 with a category attached, or 75.4%. Idorsia Pharmaceuticals US Inc accounts for 65.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $27,417 and has fallen 99.6% since, to $106 in 2025.

$56,432in general payments, 2019–2025

Across 388 payments — averaging $145.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$37K
  • Eisai Inc.$7K
  • Jazz Pharmaceuticals Inc.$5K
  • Inspire Medical Systems, Inc.$3K
  • Harmony Biosciences LLC$2K
  • Axsome Therapeutics, Inc.$533
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$1,8913%
  • Speaking & faculty fees$42,55875%
  • Travel & lodging$2,4404%
  • Food & beverage$9,43217%
  • Education$1120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few sleep medicine providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$172,922
Medicare patients
675
Services billed
1,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate19$360,910
XywavSodium,calcium,mag,pot Oxybate16$288,026
WakixPitolisant Hcl15$216,515
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine58$1,515
Trazodone Hcl65$801
Duloxetine Hcl45$595
Aripiprazole16$535
Mirtazapine37$514
Clonazepam96$453
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$383
Quetiapine Fumarate37$349
Zaleplon27$321
Bupropion XlBupropion Hcl14$290
Escitalopram Oxalate24$268
Ropinirole Hcl25$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$1,568$216,51515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few sleep medicine providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other sleep medicine in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →